Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

[1]  Sakae Tanaka,et al.  Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study , 2019, Cancer.

[2]  A. Kawai,et al.  Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes , 2019, Japanese journal of clinical oncology.

[3]  Robin L. Jones,et al.  Pazopanib in advanced soft tissue sarcomas , 2019, Signal Transduction and Targeted Therapy.

[4]  E. Stepanski,et al.  Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma , 2017, Cancer.

[5]  N. Araki,et al.  Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma† , 2016, Japanese journal of clinical oncology.

[6]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[8]  N. Araki,et al.  The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study , 2016, Cancer.

[9]  N. Araki,et al.  Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. , 2015, The Lancet. Oncology.

[10]  F. Bertucci,et al.  Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. , 2015, European journal of cancer.

[11]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[12]  J. Blay,et al.  Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. , 2011, The Lancet. Oncology.

[13]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Patrick Schöffski,et al.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  O. S. Nielsen,et al.  Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P Y Liu,et al.  Selection designs for pilot studies based on survival. , 1993, Biometrics.

[18]  Chad A. LaGrange,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .